XFinity 500 Predictions: Top 5 Picks and Best Long Shots:

As predicted, things got wild at Talladega this past Sunday as the track earned its F+ handicap-ability grade. As many top contenders were taken out at various points in the YellaWood 500, a strange “underdog” took home the checkered flag. That underdog may have also essentially clinched the season title, as Kyle Larson won at +1800 odds and boosted his championship standings lead to what seems like an insurmountable 73 points with just two races remaining. What’s more, the next track, Martinsville, has been a solid one for Larson, and expecting mechanical trouble or a race-ending wreck isn’t realistic. In fact, with Martinsville boasting a handicap-ability grade of A-, Larson is more likely to finish closer to his projected 2nd-place finish than anything else.

So while Talladega was a rich reward type of track for underdog bettors, Martinsville is far from. It is a flat short track, and anyone who has followed this column all season long knows that those tracks typically earn the highest grades on my handicap-ability scale. Thus, with a breakaway five drivers of Denny Hamlin, Larson, Christopher Bell, Joey Logano, and March winner here Chase Elliott topping the field, it’s a pretty solid bet that one of those five or a high projected driver on the final simulation will make the visit to Victory Lane at Sunday’s Xfinity 500. Of the other drivers I could see making a dent in that top 5, consider Ryan Blaney, a two-time winner here in the next gen car, and William Byron, a three-time winner, as best options. The seven drivers I have mentioned are the official favorites at DraftKings at the outset of the week, all listed at +900 or better.

Martinsville is one of the smallest tracks on the circuit, at .526 miles around, and its shape genuinely resembles a paper clip. Much of what happens here revolves around track position, as drivers running out front can easily catch up to the back of the field in a short number of laps. Holding the bottom of the track and managing the brakes are the two most important things for crews when setting up the cars. You’ll see a lot of “bump & runs,” and for drivers who are the victims, getting kicked out of line can often cost them multiple positions. Even though Martinsville isn’t nearly as physically grueling as road courses or Darlington, being packed tightly for 500 laps around this tight racing surface can be mentally tough for drivers. If you watched or bet on the race here in March, you might notice there are 100 more laps this time around. That could change the strategy the contending teams employ.

Before digging into what to look for on Sunday, here’s a quick wrap-up of what happened last week at Talladega, and how our simulation projections have fared in terms of betting results to date with two races remaining.

Initial Talladega simulation winner: Loser (-1 unit) – NOW -6.15 units for the season

Final Talladega Simulation winner: Loser (-1 unit) – NOW +26.05 units for the season (These are +82.85 units for the last two seasons!)

Final Talladega Simulation Top 2 drivers To Win: Two losers – total return -2 units – NOW +2.35 units for the season

Final Talladega Simulation Top 3 drivers To Win: Three Losers – total return -3 units – NOW -2.45 units for the season (Larson won from the 4th projected position)

Final simulation top 3 Talladega projections: three losers –total return -3 units – NOW -5.1 units for the season

Final simulation top 5 Talladega projections: one winner, four losers – total return -1.5 units – Now -42.25 units for the season

We hit on just two Top 10s with Larson +110 & Chastain +140. To show you the potential at Talladega in terms of underdogs, Cole Custer scored a Top 10 with +400 odds.

Now for my final personal picks, which are published each race day in the VSiN Email Newsletter…

Final simulation top 5 Talladega projections: five losers –total return -5 units – Now -59.8 units for the season

Top Talladega Longshots to win: six losers –total return -6 units – Now -15 units for the season

Favorites to struggle at Talladega: Elliott (36th), Gibbs (17th), Reddick (37th), Larson (1st)– Now 96 for 137 for the season, picking usual contending drivers to finish outside of the top 10.

I told you that Talladega could get wild. Hopefully you were able to take advantage of some of the other top underdogs from the simulation, like Ross Chastain, who grabbed a fourth-place finish and had a top-5 price of +350 and a top-10 price of +140. It was a truly wild YellaWood 500, even with only four official cautions. Any one of seven drivers could have won at the end had they made the right move, as Larson did. That said, overall, I feel like we are limping to the finish line this season in terms of our betting action. Hopefully we can wrap up the year with two solid runs.

Looking ahead to Martinsville on Sunday, I dug out the stats for the last four races run at this paper clip-shaped short track oval over the last two calendar years. Typically, this track is all about track position, handling, managing brakes, and clever pit decisions. Pit crews are crucial in a race like this, and most cars finish. Only 14 cars in the last five races have failed to do so. Of the simulation factors, starting position and recent history at Martinsville have stood out more than the others.

There is qualifying and practice on Saturday, and the former has proven to be far more important. In fact, of the last nine Next Gen car pole sitters, four finished second, and another won a race. That said, with what is currently a five-car breakaway at the top, I’d be surprised to see anyone outside that tightly grouped Top 5 on the projections win. Here are the stats for the last four races at Martinsville for all active drivers that have raced here, with Chase Elliott, William Byron, Denny Hamlin, and Ryan Blaney winning the races covered:

Average Starting Position for the Last Four Races at Martinsville

1. William Byron: 4

2. Chase Elliott: 5.5

3. Ty Gibbs: 6

4. Kyle Larson: 7.25

5. Joey Logano: 8

6. Alex Bowman: 9

…

22. Ryan Blaney: 22.25

23. Shane Van Gisbergen: 22.25

24. Daniel Suarez: 24.5

25. Erik Jones: 24.75

26. AJ Allmendinger: 28

27. Ricky Stenhouse: 31.75

Average Practice Speed Rank for the Last Four Races at Martinsville

1. Denny Hamlin: 2.75

2. Chase Elliott: 5

3. Ty Gibbs: 5.5

4. Darrell Wallace: 5.75

5. William Byron: 8.5

6. Christopher Bell: 10.25

…

22. Brad Keselowski: 23.75

23. Ricky Stenhouse: 24.5

24. Tyler Reddick: 25

25. Shane Van Gisbergen: 25.75

26. Chris Buescher: 30.25

27. Austin Cindric: 30.75

Average Running Position in the Last Four Races at Martinsville

1. Chase Elliott: 6

2. Kyle Larson: 6.75

3. Ryan Blaney: 7

4. William Byron: 7.25

5. Denny Hamlin: 7.5

6. Joey Logano: 8.5

…

22. Daniel Suarez: 21.25

23. Carson Hocevar: 21.25

24. Erik Jones: 21.75

25. Ricky Stenhouse: 27.25

26. Chris Buescher: 27.5

27. AJ Allmendinger: 28

Average Fastest Laps for the Last Four Races at Martinsville

1. Chase Elliott: 46.5

2. Denny Hamlin: 42.75

3. William Byron: 38.75

4. Ryan Blaney: 35.25

5. Kyle Larson: 24

6. Joey Logano: 16.25

…

22. Ross Chastain: 4.25

23. Michael McDowell: 2.75

24. Carson Hocevar: 2.75

25. AJ Allmendinger: 2.33

26. Ricky Stenhouse: 1.25

27. Erik Jones: 0

Average Driver Rating the Last Four Races at Martinsville

1. Chase Elliott: 120.48

2. Denny Hamlin: 119.03

3. Ryan Blaney: 111.85

4. Kyle Larson: 107.15

5. Joey Logano: 99.78

…

22. Carson Hocevar: 58.5

23. Daniel Suarez: 58.1

24. Erik Jones: 51.63

25. Chris Buescher: 46.45

26. AJ Allmendinger: 46.3

27. Ricky Stenhouse: 42.68

Most Average Laps Run in the Top 15 for the Last Four Races at Martinsville

1. Kyle Larson: 436.25

2. Chase Elliott: 430.5

3. Ryan Blaney: 419

4. Joey Logano: 418.75

5. William Byron: 390.75

6. Denny Hamlin: 384

…

22. Carson Hocevar: 64.25

23. Erik Jones: 44.5

24. Daniel Suarez: 44.25

25. Chris Buescher: 30.5

26. Ricky Stenhouse: 10.25

27. AJ Allmendinger: 4.67

Best Average Finish in the Last Four Races at Martinsville

1. Chase Elliott: 2.5

2. Ryan Blaney: 5

3. Kyle Larson: 5.5

4. Joey Logano: 7.25

5. William Byron: 8.5

6. Ross Chastain: 8.5

…

22. Michael McDowell: 21.75

23. Carson Hocevar: 23

24. Ricky Stenhouse: 24.25

25. Erik Jones: 24.5

26. Chris Buescher: 25.75

27. AJ Allmendinger: 26

There are some drivers with very strong resumes just from the stats above, and Hendrick Motorsports seems to be the team to beat when we come here. With those stats in mind, my top-rated drivers at Martinsville, in order, are Hamlin, Elliott, Blaney, Byron, Logano. In terms of Track Designation ratings, the top guys are Blaney, Berry, Logano, Larson, Briscoe. And finally, for recent ratings, the top 5 are Larson, Blaney, Bell, Briscoe, Logano. All of it goes into the making of my initial simulation, which can be seen now on the VSiN.com website by navigating under the SPORTS tab to AUTO RACING, then to NASCAR HUB.

The final simulation will be available Saturday afternoon after practice & qualifying, set for 1:00 p.m. ET. That said, having to make my predictions at this point (which could change a bit after practice and qualifying), I would go with the following:

Top 5: Hamlin, Elliott, Logano, Blaney, Larson

Top underdogs to consider (+1200 or higher): Wallace, Berry, Gibbs, Chastain

Favorites to struggle: Briscoe, Buescher, Hocevar, Van Gisbergen

The 500-lap event at Martinsville is set for 2:00 p.m. ET on Sunday, November 1st.

Be sure to visit VSiN.com for this week’s full initial simulation. This is where you’ll find the sims all season long. While there, you can click on driver links for season stats and recent results, plus get current odds and much, much more.

Die besten Basketball-Ligen Europas live bei MagentaSport: FCB-Coach Gavel konsterniert: "Jetzt überwiegt klar das Negative": München sucht auch gegen Barca die Balance, Frankfurt und Ulm stark

München (ots)

Nur 2 Siege nach 8 Spielen in der EuroLeague - das ist schon mehr als nur eine Ergebniskrise für den FC Bayern! Nach dem 84:88 gegen Barcelona konstatiert MagentaSport-Experte Per Günther, dass die Münchner "weit davon entfernt sind, eine wirklich gefestigte EuroLeague-Mannschaft zu sein." Trainer Anton Gavel spielt trotz der schweren Situation nicht auf Zeit: "Das ist wie bei anderen Mannschaften in der EuroLeague. Sie haben keine Zeit, wir haben genauso wenig Zeit, um zu wachsen. Vor allem auch wenig Training, was das angeht. Aber das wussten wir von Anfang an. Klar, haben wir uns vorgenommen, hier mehrere Spiele zu gewinnen. Das ist uns nicht gelungen. Wir müssen ein Spiel finden, in dem wir das einfach brechen und hoffentlich nach oben weiterschauen können." Auch Positives gibt es im Moment wenig für den Coach: "Gerade jetzt, direkt nach dem Spiel, kann man die Niederlage nicht schönreden. Das ist die nächste Niederlage, die wir zuhause kassieren müssen. Jetzt überwiegt klar das Negative."

In der Halbzeit erklärt Alan Ibrahimagic, Co-Trainer der deutschen Nationalmannschaft, die neue Aufgabenteilung zwischen ihm und Boss Alex Mumbru, seit Sommer auch als Klub-Trainer bei Bologna. "Ich bin hauptsächlich in der BBL unterwegs, weil Álex das wegen der EuroLeague-Saison nicht sehen kann. In der NBA werde ich im Januar eine Tour starten, weil wir im Hinblick auf den Sommer mit den Jungs persönlich sprechen wollen. Das übernehme ich dieses Jahr." Ibrahimagic hatte das deutsche Team während des EM-Titelgewinns und des krankheitsbedingten Ausfalls von Mumbru gecoacht.

Am 5. Spieltag des EuroCups gab es für die Frankfurt Skyliners einen deutlichen 113:97-Sieg gegen U-BT Cluj-Napoca. Sogar Trainer Klaus Perwas war durchaus zufrieden: "Defensiv waren wir nicht schlecht. Aber ich kann mich nicht erinnern, dass wir schon mal 113 Punkte gemacht haben. Das ist sicher ein gutes Ergebnis. Ich habe den Jungs gesagt, mit einem freien Kopf zu spielen, das Spiel zu genießen, hart zu spielen, das Spiel einfach zu halten."

Die Freude überwiegt auch bei ratiopharm Ulm, das bei Lietkabelis Panevezys in Litauen ein 86:68-Sieg gelang. Trainer Ty Harrelson sieht sein Team nah am Optimum: "Ich bin stolz auf das Team. Sie sind heute zusammengekommen und haben den Basketball gespielt, den wir spielen wollen. Es gibt immer noch einige Dinge, die wir verbessern können. Aber über weite Strecken haben wir richtig gut zusammengespielt."

In der Basketball Champions League erwische Bamberg einen komplett gebrauchten Abend und unterlag Pallacanestro Varese überdeutlich 61:95.

Nachfolgend die wichtigsten Clips und Stimmen vom Dienstag des 8. Spieltags der EuroLeague. Bei Verwendung bitte MagentaSport als Quelle angeben. Weiter geht es mit Basketball bei MagentaSport am Mittwoch. Ab 18.45 Uhr empfangen die NINERS Chemnitz im EuroCup Titelverteidiger Cosea JL Bourg-en-Bresse. AM Donnerstag spiel München bei Roter Stern Belgrad - live ab 19.45 Uhr.

EuroLeague | 8. Spieltag: FC Bayern München - FC Barcelona 84:88 | Bayern weiter auf der Suche nach dem ersten Heimsieg: "Wir müssen ein Spiel finden, in dem wir das einfach brechen"

Link zu den Highlights des Spiels: clipro.tv/player?publishJobID=MnRjVWx2K3AvMFpabVVBSURBVDdDK2UvckdTZ3RLWlcwMm1CdUEyNUwvYz0=

Der einzige Münchner Lichtblick neben Jo Thiemann an einem frustrierenden EuroLeague-Abend: Miles Norris mit 17 Punkten. Der Clip dazu: clipro.tv/player?publishJobID=SVBxNTNFWllUUnNYbXF2cWQxVmdYU0VqaEpzRWZRTGF1ci9oQXFQMnlPaz0=

Miles Norris, 17 Punkte, 3 Rebounds und ein Assist gegen Barcelona, darüber, was den Bayern in engen Spielen noch fehlt: "Wir müssen die kompletten 40 Minuten spielen. Letztes Spiel haben wir langsam angefangen. Heute kommen wir gut ins 1. Viertel rein. Im Lauf des Spiels müssen wir einfach besser vollstrecken."

...ob es - trotz der Niederlage - ein Schritt in die richtige Richtung war: "Definitiv! Wir hatten einfach volle Tage. Es wäre gut gewesen, ein paar Siege zu holen. Aber wir müssen jeden Tag fokussiert bleiben, Videoanalyse machen, als Team besser werden und uns jeden Tag verbessern."

...ob es mit 17 Punkten ein 'Breakthrough Game' für ihn war: "Ein bisschen. Ich mache, was ich kann, um dem Team zu helfen, zu gewinnen. Ich versuche, mit etwas Energie rauszukommen. Meine Teamkollegen haben mich an den richtigen Orten gefunden, sodass ich gut vollstrecken konnte."

Link zum Interview: clipro.tv/player?publishJobID=RE5FNEMyTzdsTGlPbGZ6clkzeXRWbFF4VFljRU9PNlVlejdOR3dycVlwaz0=

Anton Gavel, Trainer FC Bayern: "Wir haben uns fest vorgenommen, irgendwann ein Heimspiel zu gewinnen. Das war heute nicht der Fall. Wir haben im letzten Viertel nicht die nötigen Stops gemacht. Gerade wenn es wichtig war, hat uns [Kevin] Punter sehr wehgetan. Offensiv haben wir bei -3 ein Turnover. Das war ärgerlich. Wir müssen uns jetzt irgendwie aus dieser Situation rausbekommen und werden weiterhin dran arbeiten, dass wir besser werden."

...wie sich die leichten Turnover abstellen lassen: "Das ist wie bei anderen Mannschaften in der EuroLeague. Sie haben keine Zeit, wir haben genauso wenig Zeit, um zu wachsen. Vor allem auch wenig Training, was das angeht. Aber das wussten wir von Anfang an. Klar, haben wir uns vorgenommen, hier mehrere Spiele zu gewinnen. Das ist uns nicht gelungen. Wir müssen ein Spiel finden, in dem wir das einfach brechen und hoffentlich nach oben weiterschauen können."

...was man Positives aus dem Spiel mitnehmen kann: "Man kann aus jedem Spiel Positives nehmen. Aber gerade jetzt, direkt nach dem Spiel, kann man die Niederlage nicht schönreden. Das ist die nächste Niederlage, die wir zuhause kassieren müssen. Jetzt überwiegt klar das Negative."

Link zum Interview: clipro.tv/player?publishJobID=NkJKbkxnbW82eUY0cjdpaERERWw3NnJwTWl2U05CdHpWTWJQOGFTR3B6UT0=

Per Günther, MagentaSport-Experte, über die Probleme des FC Bayern in dieser EuroLeague-Saison: "Die Sorgenfalten sind gleichbleibend. Die Münchner sind besser als gegen Dubai aufgetreten [91:107, 36:63 zur Pause, Anm. d. Red.]. Das kann aber auch nicht der Anspruch sein. Alles wäre besser gewesen, als das, was wir in der 1. Halbzeit gegen Dubai gesehen haben. Das ist jetzt schon ein Brett. Du rechnest immer so auf dem kleinen Bierdeckel und sagst, du musst ungefähr die Hälfte deiner Spiele gewinnen. Jetzt bist du schon vier drunter. Du bist 2:6. Jetzt kommen vier Auswärtsspiele. Wenn es doof läuft, bist du 3:9. Dann bist du schon 6 unter dem Soll. Die musst du dir irgendwann wieder zurechtklauen. Wir sind uns alle sicher: Anton Gavel mit der Qualität als Trainer, mit dem, was an Spielerpotential da schlummert - die Münchner werden besser sein. Irgendwann werden sie in der Spur sein, dann werden sie Spiele gewinnen, dann wird die Stimmung gut sein. Aber die Frage ist: Wird der Punkt zu spät kommen, dass sie ihre Ziele erreichen? Mit jedem verlorenen Heimspiel, gerade mit den machbaren, wird diese Sorge realer, dass das zu spät klicken wird."

Link zum Interview: clipro.tv/player?publishJobID=MXV4eVRUZitpcDYzUWlTR29obzY1VmQrUGhRc2pUSmF3TGRsWlhmSVA3ND0=

Mumbrú-Co Ibrahimagic im Interview: EuroLeague - und NBA-Tour im Januar

Alan Ibrahimagic, Co-Trainer Nationalmannschaft, in der Halbzeitpause darüber, ob schon absehbar ist, wie der Kader für die Länderspiele im November aussehen wird: "Ein bisschen absehbar schon. Aber es sind noch einige Fragezeichen offen. Bei den EuroLeague-Spielern ist es noch nicht ganz sicher. Da befinden wir uns und da befindet sich Álex Mumbrú in Kontakt. Das wird noch ein bisschen dauern, bis wir wirklich Klarheit haben."

...über die Kommunikation mit Álex Mumbrú, nachdem dieser selbst einen Job in der EuroLeague, bei Virtus Bologna angenommen hat: "Die Kommunikation ist sehr gut. Wir sind immer in Kontakt. Er hat viel mit EuroLeague und der italienischen Liga zu tun. Aber wir telefonieren oft. Ich bin tatsächlich morgen dort, gegen Maodo [Lô], gegen Zalgiris. Das ist ein bisschen Vorbereitung auf das Fenster."

...wieviel er generell unterwegs ist, in der EuroLeague oder bei den Nationalspielern in der NBA: "Erstmal EuroLeague, Bayern und neuerdings Bologna. Ansonsten ist noch nichts geplant. Ich bin hauptsächlich in der BBL unterwegs, weil Álex das wegen der EuroLeague-Saison nicht sehen kann. In der NBA werde ich im Januar eine Tour starten, weil wir im Hinblick auf den Sommer mit den Jungs persönlich sprechen wollen. Das übernehme ich dieses Jahr."

...wie ein München-Trip für ihn aussieht: "Mit den Bayern-Spielern spreche ich relativ häufig, auch zwischendurch. Ich wohne in der Nähe, in Nürnberg. Ich fahre vor dem Spiel kurz her und dann wieder zurück. Aber ich habe vor ein paar Tagen oder einer Woche, als sie in Hamburg waren, ein bisschen länger mit den Bayern sprechen können. Da ist der Kontakt ziemlich gut."

...wie wichtig für ihn und das Trainerteam die Leistungen in der EuroLeague sind: "Sie kennen ihre Rolle [in der Nationalmannschaft]. Dann sind sie in einem System, in dem sie sich wohlfühlen. Aber ich glaube, wie Per gesagt hat, was für Daniel [Theis] gilt, gilt für alle: Wenn sie in relevanten Teams auf hohem Niveau um etwas spielen, hilft das ihrer persönlichen Entwicklung und damit auch der Nationalmannschaft."

...wie sein NBA-Trip aussieht: "Jeder Spieler wird besucht. Mit Ariel [Hukporti] haben wir ein Fragezeichen, wie es mit der Recovery und der Reha weitergeht, wo er sein wird. Da sind wir uns noch nicht sicher. Ansonsten besuchen wir alle NBA-Spieler. Unter anderem auch Franz. Sie haben viel Talent, einen neuen Trainer. Ein bisschen Geduld haben sie und werden sie auch brauchen. Aber ich glaube, dass das eine ziemlich gute Saison für sie sein könnte."

...über Dennis Schröder: "Er wird immer relevant sein. Er weiß, wenn er eine Rolle hat, spielt er auf jeden Fall viel besser.

LAS VEGAS, Oct. 27, 2026 /PRNewswire/ -- Las Vegas Sands Corp. (NYSE: LVS) today announced that its majority-owned subsidiary, Sands China Ltd. ("Sands China"), has priced $700 million of 6.400% senior notes due 2032 and $300 million of 6.700% senior notes due 2033. The offering is expected to close on November 3, 2026, subject to customary closing conditions.

Sands China intends to use the net proceeds of approximately $989 million from the offering and cash on hand to redeem in full the outstanding principal amount of its US$700 million 2.300% senior notes due 2027 and any accrued interest, repay the outstanding balance on its 2024 SCL Revolving Facility and for general corporate purposes, including capital expenditures.

The notes have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any other jurisdiction, and are being offered and sold only to professional investors (as defined in Chapter 37 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("Hong Kong Listing Rules") that are qualified institutional buyers (in reliance on Rule 144A under the Securities Act) and/or non-U.S. Persons outside the United States (in reliance on Regulation S under the Securities Act)). None of the notes are being offered or sold to the public in Hong Kong and none of the notes will be placed to any connected person (as defined in the Hong Kong Listing Rules) of Sands China.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Sands China proposes to seek a listing of the notes on the Hong Kong Stock Exchange and has received an eligibility letter from the Hong Kong Stock Exchange for the listing of the notes. Admission of the notes to the Hong Kong Stock Exchange and quotation of any notes on the Hong Kong Stock Exchange is not to be taken as an indication of the merits of Sands China or the notes.

About Las Vegas Sands Corp. (NYSE: LVS)

Sands is the leading global developer and operator of integrated resorts. The company's iconic properties drive valuable leisure and business tourism and deliver significant economic benefits, sustained job creation, financial opportunities for local businesses and community investment to help make its host regions ideal places to live, work and visit.

Sands' portfolio of properties includes Marina Bay Sands® in Singapore and The Venetian® Macao, The Londoner Macao®, The Parisian® Macao, The Plaza® Macao and Four Seasons® Hotel Macao, and Sands® Macao in Macao SAR, China, through majority ownership in Sands China Ltd.

Dedicated to being a leader in corporate responsibility, Sands is anchored by the core tenets of serving people, communities and the planet. The company's ESG leadership has led to inclusion on the Dow Jones Best-in-Class Indices for World and North America, as well as Fortune's list of the World's Most Admired Companies.

About Sands China Ltd.

Sands China Ltd. (Sands China or the Company) is incorporated in the Cayman Islands with limited liability and is listed on The Stock Exchange of Hong Kong Limited (HKEx: 1928). Sands China is the largest operator of integrated resorts in Macao. The Company's integrated resorts on the Cotai Strip comprise The Venetian® Macao, The Plaza® Macao, The Parisian Macao and The Londoner® Macao. The Company also owns and operates Sands® Macao on the Macao peninsula. The Company's portfolio features a diversified mix of leisure and business attractions and transportation operations, including large meeting and convention facilities; a wide range of restaurants; shopping malls; world-class entertainment at The Venetian Arena, The Londoner Arena, The Venetian Theatre, The Parisian Theatre, the Londoner Theatre and the Sands Theatre; and a high-speed Cotai Water Jet ferry service between Hong Kong and Macao. The Company's Cotai Strip portfolio has the goal of contributing to Macao's transformation into a world centre of tourism and leisure. Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks, uncertainties or other factors, which may cause material differences in actual results, performance or other expectations. These factors include, but are not limited to, current market demand for these types of securities and the securities of Sands China Ltd., Sands China Ltd.'s ability to consummate the offering in the currently anticipated timeframe or at all, and the negotiations between Sands China Ltd. and the initial purchasers. Forward-looking statements in this press release are based on information available to Sands China Ltd. and Las Vegas Sands Corp. at this time and each of Sands China Ltd. and Las Vegas Sands Corp. assumes no obligation to update such information.

SOURCE Las Vegas Sands Corp.

Share this article

Season Features Three Ships in Australia & New Zealand with the Longest Ever Roundtrip World Cruise From Australia Visiting 61 Destinations Across 31 Countries

FORT LAUDERDALE, Fla., Oct. 27, 2026 /PRNewswire/ -- Princess Cruises unveils its 2028â29 Australia and New Zealand season alongside the 2029 Grand World Odyssey. Together, this collection offers four experiences in one extraordinary season spanning the spectacular landscapes of Australia, New Zealand and the South Pacific, as well as some of the world's most celebrated cities and remote destinations. All voyages go on sale November 10, 2026.

"Princess Cruises has a long and proud history of inspiring guests to explore the world, and our 2028â29 season takes that spirit of discovery to extraordinary new heights," said Jim Berra, Princess Cruises Chief Commercial Officer. "From the longest World Cruise ever to sail roundtrip out of Australia to an unmatched variety of voyages showcasing the beauty of Australia, New Zealand and the South Pacific, we're giving guests more ways to discover remarkable destinations, immerse themselves in different cultures and see the world in new ways."

2029 Grand World Odyssey: 129 Nights of Extraordinary Discovery

The longest World Cruise ever offered roundtrip from Australia, the 2029 Grand World Odyssey promises an adventure of a lifetime, connecting five continents and some of the planet's most fascinating destinations.

Sailing aboard Grand Princess, the 129-night Grand World Odyssey spans approximately 37,300 nautical miles and visits 61 destinations across 31 countries. Along the way, guests will experience the cultural treasures of Europe and the Mediterranean, the natural wonders of the South Pacific, the vibrant cities of the Americas, and some of the world's most remote islands all in one unforgettable global adventure.

Highlights of the 2029 Grand World Odyssey include:

- 129 Nights, Five Continents: An extraordinary journey spanning approximately 37,300 nautical miles, visiting 61 destinations in 31 countries.

- 51 UNESCO World Heritage Sites: Opportunities to discover some of the world's most treasured cultural, historical and natural landmarks.

- More Time Ashore: Nine More Ashore experiences throughout Europe, South America and the South Pacific, including eight late-night stays and one overnight call, allowing guests to experience destinations beyond traditional daytime visits.

- Iconic Cities & Destinations Around the World: Visits to New York City, Miami, Reykjavik, Lisbon, Barcelona, Copenhagen, Tahiti and Auckland, among other celebrated destinations.

- Panama Canal Adventure: Two full transits through the Panama Canal's new locks, one of the world's most impressive engineering achievements.

- Remote Island Discovery: Scenic cruising near Easter Island, famous for its mysterious moai statues, and Pitcairn Island, one of the world's most isolated inhabited islands and home to descendants of the HMS Bounty mutineers.

- A Truly Global Journey: Crossing the Equator twice and the International Date Line twice, connecting extraordinary destinations across multiple oceans and hemispheres.

Guests can begin their World Cruise adventure from Sydney, Brisbane or Melbourne, with an additional departure opportunity from Dover, the gateway to London.

2028â29 Australia & New Zealand: More Ways to Explore Down Under

Princess' 2028â29 Australia and New Zealand program delivers exceptional itinerary variety with over 90 departures across over 70 unique itineraries aboard three ships. Voyages range from two to 46 nights, offering guests everything from short escapes to extended adventures exploring the region's spectacular coastlines, vibrant cities, extraordinary wildlife and rich cultural heritage.

Season highlights include:

- Three Princess Ships: Grand Princess, Emerald Princess and Royal Princess sailing throughout the region.

- 42 Destinations Across Six Countries: Exploring the diverse landscapes, cultures and natural wonders of Australia, New Zealand and the South Pacific.

- 10 UNESCO World Heritage Sites: Opportunities to discover some of the region's most significant natural and cultural treasures.

- 11 More Ashore Experiences: Late-night and overnight port calls providing additional time to explore.

- Six Departure Ports: Convenient sailings from Adelaide, Auckland, Brisbane, Melbourne, Perth (Fremantle) and Sydney.

- 17 Round Australia Voyages: Extended journeys showcasing Australia's remarkable coastline and diverse destinations.

The season also marks the welcome return of Emerald Princess to Australia for the first time since the 2016-17 season, along with renewed homeporting opportunities in Melbourne and an expanded selection of New Zealand cruising.

Extraordinary Wildlife, Natural Wonders and Cultural Discoveries

From encounters with Australia's iconic wildlife to breathtaking scenic cruising, the 2028â29 season offers memorable experiences both on land and at sea.

Among the standout destinations and experiences:

- Phillip Island, Australia â The Little Penguin Parade: Witness one of Australia's most beloved wildlife spectacles as hundreds of Little Penguins, the world's smallest penguin species, emerge from the ocean at sunset and make their way across the beach to their burrows.

- Kangaroo Island, Australia â Wildlife in Its Natural Habitat: Discover one of Australia's premier wildlife destinations, where kangaroos roam freely, koalas rest in eucalyptus trees, Australian sea lions gather along pristine beaches and rare birdlife thrives.

- Kimberley Coast, Australia â Ancient Landscapes and Dramatic Scenery: Experience the remote beauty of Australia's northwest coast, where towering red cliffs, dramatic gorges, cascading waterfalls and untouched islands reveal landscapes shaped over billions of years.

- New Zealand â Spectacular Scenery and Coastal Discovery: Explore Fiordland National Park and the country's breathtaking landscapes, charming coastal communities and remarkable natural beauty through an expanded selection of itineraries across both the North and South Islands.

- South Pacific â Tropical Island Escapes: Discover island destinations known for turquoise waters, welcoming cultures, lush landscapes and laid-back tropical charm.

More Time to Experience Every Destination

Combined with Princess' signature onboard hospitality, exceptional dining, entertainment and relaxing accommodations, the 2028â29 season offers an exceptional way to explore Australia, New Zealand and beyond with Princess shore excursions.

Booking Information

Princess is offering an Early Booking Bonus on 2028-29 Australia and New Zealand voyages with up to $500 instant savings, up to $500 onboard credit, reduced $100 deposits, early access to dining reservations and arrival groups, a free location upgrade and up to $300 in savings for Captain's Circle members. The Early Booking Bonus for the 2029 Grand World Odyssey cruise includes up to $3,000 in onboard credit plus up to $2,000 in Captain's Circle savings. Both offers are available from November 10, 2026, through February 16, 2027.

Additional information about Princess Cruises is available through a professional travel advisor, by calling 1-800-PRINCESS (1-800-774-6237) or visiting www.princess.com.

About Princess Cruises:

Princess Cruises, the original Love Boat, has been creating enriching vacations shaped by discovery, human connection, and personalized service for more than 60 years. Sailing to more than 345 destinations in over 90 countries across all seven continents, Princess invites millions of guests to experience new places, people, and cultures in meaningful ways. Recognized as the world's most iconic cruise brand, Princess is known for thoughtfully curated global itineraries, well-appointed staterooms, exceptional dining and entertainment, and immersive experiences onboard and ashore. By bringing together thoughtful service, elevated experiences, and extraordinary destinations, Princess creates meaningful moments, lasting connections and stories worth sharing long after the journey ends. Princess Cruises is part of Carnival Corporation, the world's largest cruise company, with a portfolio of cruise lines operating in more than 800 ports and destinations worldwide (NYSE: CCL).

SOURCE Princess Cruises

Note to editors

Newsroom: Additional media information is available at princess.com/news, http://www.princess.com/news

Share this article

Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis

HANGZHOU, China, SHANGHAI and BOSTON, Oct. 27, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase III clinical trial evaluating zemprocitinib, an investigational, selective, second-generation oral Janus kinase 1 (JAK1) inhibitor, in adult patients with moderate-to-severe active rheumatoid arthritis (RA) who had experienced inadequate response or intolerance to biologic disease-modifying antirheumatic drugs (bDMARDs).

The study met its primary endpoint of ACR20 response and key secondary endpoints at Week 24, demonstrating a statistically significant improvement with zemprocitinib versus placebo (p0.0001). The Week 52 and Week 76 results further demonstrate continued improvements in all disease activity measurements and physical function during long-term treatment by Week 52 and sustained clinical responses through Week 76.

The double-blind, placebo-controlled Phase III study randomized 430 patients with moderate-to-severe active RA who had experienced an inadequate response or intolerance to prior bDMARDs, of whom 429 received at least one dose of study treatment. During the initial 24-week double-blind treatment period, patients received zemprocitinib 12 mg twice daily or placebo. Following this period, patients continued or transitioned to active treatment, with efficacy and safety assessed through Week 76.

Long-Term Sustained Efficacy Through Week 76

Among patients receiving continuous zemprocitinib treatment, ACR20, ACR50, and ACR70 response rates were 93.0%, 79.9%, and 52.5%, respectively, at Week 52. Responses remained at Week 76, with ACR20 and ACR50 rates of 91.8% and 80.5%, respectively, while ACR70 increased to 62.4%, demonstrating sustained ACR responses during long-term treatment.

Beyond ACR responses, zemprocitinib demonstrated sustained improvements across measures of disease activity, clinical remission and physical function through Week 76 (selected data are presented in the table below). At Week 52 and Week 76, among patients receiving continuous zemprocitinib treatment, 85.5% and 81.4% achieved low disease activity, respectively, defined as disease activity score (DAS28(CRP) â¤3.2). Based on the clinical disease activity index (CDAI), 81.5% and 81.0% of patients achieved low disease activity (CDAI â¤10), respectively. Improvements in physical function were also observed with 84.5% and 86.7% of patients achieving an improvement of at least 0.22 points in the health assessment questionnaireâdisability index (HAQ-DI) from baseline at Week 52 and Week 76, respectively.

Selected efficacy results in patients receiving zemprocitinib 12 mg twice daily*:

Abbreviations: ACR, American College of Rheumatology; DAS28(CRP), Disease Activity Score 28 joints using C-reactive protein; CDAI, Clinical Disease Activity Index; HAQ-DI, Health Assessment QuestionnaireâDisability Index.

*The 24-week results of efficacy and safety of zemprocitinib, in patients with rheumatoid arthritis from the Phase III COURAGE-RA study, were presented at the EULAR 2026 Congress (Abstract #OP0208). The EULAR 2026 abstract archive can be found here.

Patients who initially received placebo and switched to zemprocitinib at Week 24 also demonstrated increased clinical responses by Week 76, with ACR20, ACR50, and ACR70 response rates of 92.0%, 77.6%, and 55.1%, respectively, and achieved comparable responses in all other efficacy measurements comparing the patients with continuous dosing of zemprocitinib through Week 76. These findings complement the sustained ACR responses and provide a broader picture of long-term clinical outcomes in patients who had an inadequate response or intolerance to bDMARDs.

Long-Term Safety and Tolerability Through Week 76

During the initial 24-week double-blind, placebo-controlled period, the safety profile of zemprocitinib was generally comparable to that of placebo as reported at EULAR 2026*. The safety profile remained consistent through Week 76 with no new safety signals identified during long-term treatment. An additional observation was the cleaner lab parameters suggesting a cleaner profile of zemprocitinib, particularly with the increase in mean hemoglobin levels, rare incidence of grade 3 or 4 in ALT elevations and grade 3 in AST elevations, and the lack of reports on grade 4 AST elevations. These findings provide additional information on the safety and tolerability of zemprocitinib during long-term treatment in patients with RA.

Professor Xiaofeng Zeng, Principal Investigator of the study from Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, said: "Treatment options remain limited for patients with difficult-to-treat rheumatoid arthritis, leaving significant unmet medical needs. The long-term results from the Phase III clinical study of zemprocitinib are very encouraging. We observed favorable efficacy not only in patients who had an inadequate response or intolerance to bDMARDs, but also in patients who had an inadequate response to prior JAK inhibitor therapy. Zemprocitinib also demonstrated a favorable long-term safety profile. These findings suggest that zemprocitinib may offer an important additional treatment option for patients whose disease remains inadequately controlled with existing therapies."

"These long-term results represent an important milestone in the clinical development of zemprocitinib," said Dr. Zhao-Kui (ZK) Wan, Founder and CEO of Lynk Pharmaceuticals. "We are encouraged by the sustained clinical responses and safety profiles observed through Week 76 in patients who had an inadequate response or intolerance to prior biologic therapies. These findings add to the clinical evidence supporting the continued development of zemprocitinib for patients with rheumatoid arthritis."

"We are encouraged by the long-term efficacy and safety results from the Phase III study of zemprocitinib, which provide further clinical evidence of its best-in-class potential as a treatment option for patients with moderate-to-severe rheumatoid arthritis," said Dr. Aik Goh, Chief Medical Officer of Simcere Pharmaceutical Group. "As the commercialization partner for zemprocitinib in Greater China, we look forward to helping address the unmet treatment needs of patients with rheumatoid arthritis in China soon."

About Zemprocitinib

Zemprocitinib is an investigational, orally administered, selective second-generation JAK1 inhibitor discovered and developed by Lynk Pharmaceuticals. It is being developed for inflammatory and autoimmune diseases, including rheumatoid arthritis, atopic dermatitis, and ankylosing spondylitis. In addition to its RA development program, zemprocitinib has completed a pivotal Phase III study in atopic dermatitis, and a New Drug Application has been submitted to and accepted for review by China's National Medical Products Administration. A Phase III clinical program in ankylosing spondylitis is also underway. In March 2022, Lynk Pharmaceuticals entered into a commercialization collaboration with Simcere to jointly advance the commercialization of zemprocitinib for rheumatoid arthritis and ankylosing spondylitis in Greater China.

About the Phase III Rheumatoid Arthritis Study

The Phase III study was a randomized, double-blinded, placebo-controlled clinical trial evaluating the efficacy and safety of zemprocitinib in adults with moderate-to-severe active rheumatoid arthritis (RA) who had experienced an inadequate response or intolerance to prior biologic disease-modifying antirheumatic drugs (bDMARDs).

A total of 430 patients were randomized, of whom 429 received at least one dose of study treatment. The primary efficacy endpoint was the proportion of patients achieving an ACR20 response at Week 24. Key secondary endpoints included ACR50 response and DAS28(CRP) â¤3.2 at Week 24.

Following the initial 24-week double-blind treatment period, patients continued or transitioned to active treatment, with long-term efficacy and safety assessed through Week 76, followed by a 4-week safety follow-up period.

About Simcere:

Simcere Pharmaceutical Group Limited (02096) is a pharmaceutical company driven by innovation and focusing on four therapeutic areas including Neuroscience, Oncology, Autoimmune Diseases and Anti-infection. We proactively explore areas with significant unmet needs, and our mission is for patients, for life. Driven by our in-house R&D efforts and synergistic innovation, Simcere has established strategic cooperation partnerships with many innovative companies and research institutes.

About Lynk Pharmaceuticals

Lynk Pharmaceuticals is a clinical-stage innovative drug company focused on autoimmune and inflammatory diseases, committed to addressing unmet clinical needs through first-in-class innovation, developing differentiated small-molecule therapies, and providing superior oral alternatives to biologics. The company was founded by senior R&D leaders from Pfizer, MSD, and Johnson & Johnson, focusing on the JAK-STAT and expanding to TYK2 signaling pathways, and mastering targeted protein degradation.

The company combines AI-assisted drug design, comprehensive biological evaluation, and protein degradation technologies into an integrated innovative R&D platform spanning target discovery, molecular design, translational research, and clinical development to advance differentiated therapies for patients worldwide. To date, Lynk Pharmaceuticals has successfully developed and progressed multiple Class 1 new drug candidates and advanced multiple pipeline programs through internal research and development as well as global partnerships.

- Grants Astellas exclusive option to obtain worldwide license to develop and commercialize DAX-044, with Audax having the option to co-fund and co-promote DAX-044 in Australia and New Zealand -

- Audax will fund and continue DAX-044 development into Phase 1 -

- Total potential transaction value of up to US$1.34 billion, excluding royalties -

TOKYO and MELBOURNE, Australia, Oct. 27, 2026 /PRNewswire/ -- Astellas Pharma Inc. [TSE: 4503, President and CEO: Naoki Okamura, "Astellas"] and Audax Biosciences Pty Ltd ("Audax") today announced that they have entered into an exclusive option and license agreement for DAX-044, Audax's lead immuno-oncology AVIKINE® candidate. Under the agreement, Astellas receives an exclusive option which, on exercise, will grant Astellas a worldwide license to develop, manufacture and commercialize DAX-044. Audax has the option to co-fund and co-promote DAX-044 in Australia and New Zealand. The agreement further strengthens Astellas' pipeline in Immuno-Oncology, one of the Primary Focuses of Astellas' R&D strategy and complements its portfolio of targeted immunotherapy approaches.

Takahiko Iwaya, Chief Strategy Officer, Astellas

"At Astellas, we are committed to advancing innovative approaches that have the potential to address significant unmet needs for patients with cancer. DAX-044 is a promising investigational immuno-oncology program with a differentiated mechanism designed to selectively activate anti-tumor immune responses. By combining Audax's innovative science with Astellas' development, manufacturing and commercialization expertise, we hope to advance a potential new treatment option for patients with solid tumors, including cancers where effective immune stimulation remains an important therapeutic challenge."

Jai Rautela, Ph.D., MBA, Chief Executive Officer, Audax Biosciences

"Astellas shares our pioneering spirit in immuno-oncology making them an ideal partner for highly differentiated programs such as DAX-044. This partnership will expedite the planned phase 1 clinical evaluation of DAX-044 for the benefit of patients with various types of solid tumor. This transaction demonstrates confidence in our approach to novel therapeutic development and potential in co-developing DAX-044 in our home market."

DAX-044 is an investigational, immune-targeted interleukin-12 (IL-12) antibody-cytokine fusion, designed with AVIKINE® technology to concentrate IL-12's immune-activating activity within the tumor microenvironment while limiting the systemic toxicity that has historically constrained IL-12-based therapy. DAX-044 has demonstrated a potential best-in-class therapeutic index for an IL-12 agent in preclinical studies and is currently in IND/CTN-enabling development.

Under the terms of the agreement, Audax will receive up front and potential future option exercise payment totaling US$285 million and continue development of DAX-044 into a Phase 1 study expected to commence in 2027. Upon exercising its option, Astellas will assume sole responsibility for global development, manufacturing and commercialization, with Audax having the option to co-fund and co-promote DAX-044 in Australia and New Zealand. In addition, Audax will be eligible to receive development and commercial milestone payments of up to US$1.05 billion, as well as tiered double-digit royalties on worldwide net sales of DAX-044, if approved. Exercise of the option is subject to customary conditions, including receipt of applicable antitrust clearances.

About Astellas

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.

About Audax Biosciences

Audax Biosciences is an Australian biotechnology company developing next-generation immunotherapies for cancer and other immune-related diseases. We develop novel solutions to the most difficult immunology problems to bring hope to patients underserved by today's medicines. Our preclinical portfolio includes additional AVIKINE® programs and other undisclosed modalities tailored to each disease we aim to cure. Learn more at www.audax.bio.

Astellas Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Audax Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the potential payments under the agreement, the development and therapeutic potential of DAX-044, and the timing of clinical activities. These statements are based on Audax's current assumptions and expectations and involve known and unknown risks and uncertainties inherent in drug development, including the risk that the option is not exercised and that milestone payments are never received. Actual results may differ materially. Audax undertakes no obligation to update these statements except as required by law.

SOURCE Astellas Pharma Inc.

Share this article

MONTREAL, Oct. 27, 2026 /PRNewswire/ -- Strategic Resources Inc. (TSXV: SR) (FSE: UI8) (the "Company") announces that it has scheduled its next Annual General Meeting of Shareholders for December 16, 2026 at 9:00 am EDT in Montreal and announces that Michael Moore, a member of its Board of Directors, has resigned. Michael served on a few Board committees and will be missed by the Strategic Resources management team.

About Strategic Resources

Strategic Resources (TSXV:SR) is a critical mineral development company focused on vanadium, high-purity iron and titanium; metals needed to decarbonize the global economy. Our main projects are the construction-ready BlackRock Project in Quebec and the previously operated Mustavaara Mine in Finland. Phase 1 of the BlackRock Project envisages a 4 million tonne per year high-purity iron ore pelletizer at Port Saguenay, Quebec with full access to the St. Lawrence Seaway. The Company's Head Office is in Montreal, Québec.

Further details are available on the Company's website at https://strategic-res.com/. To follow future news releases, please sign up at https://strategic-res.com/contact/.

Follow us on: Twitter or LinkedIn.

STRATEGIC RESOURCES INC.

Signed: "Sean Cleary"

Sean Cleary, CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Information

Certain statements and information herein, including all statements that are not historical facts, contain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking statements or information can be identified by the use of words such as "will" or "projected" or variations of those words or statements that certain actions, events or results "will", "could", "are proposed to", "are planned to", "are expected to" or "are anticipated to" be taken, occur or be achieved.

Although management of the Company believes that the assumptions made and the expectations represented by all forward-looking statements or information are reasonable, there can be no assurance that a forward-looking statement or information herein will prove to be accurate. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. These factors include, but are not limited to: risks associated with the business of the Company; business and economic conditions in the mining industry generally; the supply and demand for labour and other project inputs; changes in commodity prices; changes in interest and currency exchange rates; risks relating to inaccurate geological and engineering assumptions (including with respect to the tonnage, grade and recoverability of reserves and resources); risks relating to unanticipated operational difficulties (including failure of equipment or processes to operate in accordance with specifications or expectations, cost escalation, unavailability of materials and equipment, government action or delays in the receipt of government approvals, industrial disturbances or other job action, and unanticipated events related to health, safety and environmental matters); risks relating to adverse weather conditions; political risk and social unrest; changes in general economic conditions or conditions in the financial markets; and other risk factors as detailed from time to time in the Company's continuous disclosure documents filed with Canadian securities administrators. Strategic does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

SOURCE Strategic Resources Inc.

Share this article

PORTAGE, Ind., Oct. 27, 2026 /PRNewswire/ -- Ports of Indiana-Burns Harbor has been awarded $11.2 million through the U.S. Department of Transportation's Maritime Administration (MARAD) Port Infrastructure Development Program (PIDP) to modernize its cargo handling, including the specialized equipment needed to support future international container service. The grant is part of a $498 million investment announced today by U.S. Transportation Secretary Sean P. Duffy to modernize 35 port projects across 19 states and strengthen America's supply chains.

"Indiana is the Crossroads of America, and our ports are a big part of what makes that true," said Governor Mike Braun. "This investment helps Burns Harbor move more goods faster and gives Hoosier farmers and manufacturers a more direct path to customers around the world."

"This grant is a smart investment in Indiana's port infrastructure," said Ports of Indiana Chief Financial Officer Erica Jackson. "Paired with our own funding, it puts existing docks and terminal space to work and creates new revenue to support the port long term. We are grateful to our congressional partners, Secretary Duffy and MARAD for their partnership."

The Burns Harbor Container Handling Modernization Project will fund a mobile harbor crane, bulk-handling attachments, reach stackers, a top handler, off-road yard trucks, and more. The equipment will also strengthen the port's existing operations. The mobile harbor crane can switch between bulk grabs, breakbulk lifting gear, and container spreaders allowing Burns Harbor to handle more steel, bulk materials, construction materials and project cargo alongside future container traffic when market demand arises. The $14 million project includes a $2.8 million match from Ports of Indiana.

"Indiana's location along the Great Lakes gives our state a unique advantage in moving goods and supporting American commerce," said U.S. Senator Todd Young. "Securing the federal investment needed to expand Burns Harbor's shipping capabilities, create new opportunities for Indiana businesses, and strengthen our state's role in domestic and international trade has been a priority of mine for years. I thank Secretary Duffy for his partnership in supporting this important project."

Supporting Quotes:

"Burns Harbor is the beating heart of Indiana's economy," said U.S. Senator Jim Banks. "This is a major grant to support the port's Container Handling project and modernize its operations. I appreciate Secretary Duffy and the Department of Transportation recognizing the value of this project to Indiana."

"Congratulations to Ports of Indiana-Burns Harbor on securing this critical federal funding to further enhance economic development and job-creation in Northwest Indiana," said Congressman Frank Mrvan. "Let us build on these successful initiatives with all local, state, and federal officials to continue to support our region's world-class manufacturing workforce and capabilities."

About Ports of Indiana: Ports of Indiana is a statewide port authority operating three ports on the Ohio River and Lake Michigan. Established in 1961, Ports of Indiana is a self-funded enterprise dedicated to growing Indiana's economy by developing and maintaining a world-class port system and by serving as a statewide resource for maritime issues, international trade, and multimodal logistics. For additional information, visit www.portsofindiana.com.

SOURCE Ports of Indiana

Share this article

Did you buy QBTS securities between February 26, 2026 and August 25, 2026?

Affected QBTS Investor Summary

- Who: D-Wave Quantum Inc. (NASDAQ: QBTS)

- What: Securities fraud class action lawsuit filed

- Class Period: February 26, 2026 through August 25, 2026

- Deadline to Seek Lead Plaintiff Status: December 15, 2026

- Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's financial and operational prospects

- Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options

RADNOR, Pa., Oct. 27, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against D-Wave Quantum Inc. (D-Wave) (NASDAQ: QBTS) on behalf of those who purchased or acquired D-Wave securities between February 26, 2026 and August 25, 2026, inclusive. The lawsuit is filed in the United States District Court for the Northern District of California and is captioned Fessler v. D-Wave Quantum Inc., No. 5:26-cv-11953 (N.D. Cal.). Investors have until December 15, 2026, to file for lead plaintiff status.

CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:

If you purchased or acquired D-Wave securities and have lost money on your investment, please provide your information here: https://www.ktmc.com/qbts-dwave-quantum-inc-class-action-lawsuit?utm_campaign=hc?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=qbts&mktm=PR

You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney.

To view the D-Wave video on YouTube, click here: https://youtu.be/1-ab4w_SeA4?si=nQXXTpj3fahTFlFp

D-WAVE QUANTUM INC. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:

D-Wave is in the business of developing and delivering quantum computing systems, software, and services.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Defendants materially overstated the company's operational and financial prospects; (2) as a result, it was reasonably likely that D-Wave would experience a negative impact to its business and reputation; and (3) as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHY DID D-WAVE'S STOCK DROP?

On August 6, 2026, D-Wave reported disappointing financial results for the second quarter of 2026 including, among other items, missing analysts' revenue expectations. On this news, the price of D-Wave's stock fell by $1.99 per share, or 9.28%, to close at $19.41 per share on August 6, 2026.

Then, on August 25, 2026, D-Wave issued a press release announcing the resignation of its CFO, effective September 2, 2026. On this news, the price of D-Wave's stock fell $1.84 per share, or 9.51%, closing at $17.52 per share on August 26, 2026.

WHAT D-WAVE QUANTUM INC. INVESTORS CAN DO NOW:

- File to be lead plaintiff by December 15, 2026.

- Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you.

- Retain counsel of choice or take no action.

THE LEAD PLAINTIFF PROCESS FOR D-WAVE QUANTUM INC. INVESTORS:

D-Wave investors may, no later than December 15, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages D-Wave investors to contact the firm for more information.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. The complaint in this matter was not filed by KTMC.

CONTACT:

Jonathan Naji, Esq.

(484) 270-1453

280 King of Prussia Road

Radnor, PA 19087

[email protected]

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

SOURCE Kessler Topaz Meltzer & Check, LLP

Share this article

Shorenstein Acquires 148 Lafayette Street in Manhattan's SoHo Neighborhood

Acquisition Marks Final Investment in Fund 14 and Reflects Continued Focus on High-Quality Office Properties with Strong Cash Flow and Rent Growth Potential

SAN FRANCISCO, Oct. 27, 2026 /PRNewswire/ -- Shorenstein Investment Advisers ("Shorenstein" or the "Company"), an owner and operator of high-quality office, residential and mixed-use properties across the U.S., today announced the acquisition of 148 Lafayette Street (the "Property"), a 154,000-square-foot, Class A office and retail property in Manhattan's SoHo neighborhood. The transaction marks the final investment in Shorenstein Realty Investors Fourteen, the Company's value-added real estate fund, and reflects its continued focus on acquiring high-quality, income-producing assets in markets positioned for long-term rent growth.

Located at the corner of Lafayette and Howard Streets in Manhattan's SoHo submarket, 148 Lafayette is a 12-story office building with an additional penthouse level. The building was recently renovated to create a modern, highly amenitized workplace environment, including 13' slab-to-slab ceilings, oversized windows, a modern attended lobby and two terraces for tenant use. The building is also LEED Gold certified and benefits from convenient access to multiple subway lines and the surrounding neighborhood's retail, dining and cultural amenities.

The Property is 100% leased to a diverse roster of tenants, including General Catalyst, Graphite, WeWork, Keystone Strategy and Charlotte Tilbury, with a weighted average remaining lease term of approximately nine years. Recent leasing activity has strengthened the Property's tenant roster and demonstrated the potential for continued rent growth, with approximately 70% of the current rent roll signed since January 2025.

"148 Lafayette is a compelling addition to our portfolio, combining strong in-place cash flow, a high-quality tenant roster and meaningful opportunities for future rent expansion," said Sean Fay, Senior Vice President, Investments Group at Shorenstein. "SoHo's appeal to technology and venture capital firms, together with its limited supply of high-quality office space, makes it an attractive submarket for investment and future growth. We see an opportunity to build on the Property's recent leasing momentum through active asset management."

Supported by attractive bank financing and SoHo's strong leasing fundamentals, Shorenstein is well positioned to capitalize on the Property's stable cash flow and opportunities for continued rent growth. Sustained demand from creative, technology, venture capital and other businesses, coupled with limited supply of high-quality office space, reinforces Shorenstein's strategy of targeting income-producing assets in markets where active leasing and asset management can drive long-term value creation.

Since June 2024, Shorenstein has been one of the most active office investors in the country, acquiring 14 office properties totaling approximately $2 billion. Shorenstein's strategy has focused on acquiring high-quality assets in premier submarkets that are positioned to deliver attractive cash flow and near-term value creation. Combined, the 14 office properties are producing an average distribution yield of 8% as of September 2026.

"We are proud of the portfolio of top tier office assets we've assembled for Fund XIV that produce attractive cash flow yields and opportunistic total returns, a combination that is rare to find in commercial real estate," said Colby Wick, Chief Investment Officer at Shorenstein. "With a growing pipeline of high-quality office offerings and an extremely limited amount of investment capital for the sector, we are excited about the current investment environment."

About Shorenstein

Shorenstein is a privately-owned investment adviser that, through affiliated entities, owns and operates high-quality office, residential and mixed-use properties across the U.S., with offices in San Francisco and New York. Since 1992, Shorenstein and its affiliates have acquired $20.6 billion in assets (as of June 30, 2026). Using their integrated investment and operating capabilities, the firm seeks to take advantage of opportunities that, at the particular time in the investment cycle, offer attractive returns. Investments have included ground-up developments, asset repositioning and stabilized assets; investment structures have included asset acquisitions, mezzanine loans, preferred equity investments and structured joint ventures. More information is available at www.shorenstein.com. 

Contacts

For Shorenstein:

Madeline Jones / Alexander Wolfsohn

Joele Frank, Wilkinson Brimmer Katcher

212.355.4449

SOURCE Shorenstein Properties LLC

Share this article